Skip to main content
Industry News
Givosiran provides long-term benefits in AHP, study finds
7/1/2020

A late-stage trial showed that patients with acute hepatic porphyria saw therapeutic effects from treatment with givosiran after 12 months, and the drug maintained safety and efficacy during that time period. The number of patients who did not experience attacks rose from 50% in the first six months to 61.7% in the next six months.

Full Story: